Azitra, Inc. Announces New Preclinical Data to Be Presented at the American Society of Gene and Cell Therapy Meeting

April 22, 2024 8:30 PM EDT

- Azitra will present two oral presentations at ASGCT (American Society of Gene and Cell Therapy) Baltimore, MD, May 7-11, 2024 related to ATR-12, Azitra’s candidate for Netherton syndrome
- Topical application of ATR-12 to ex vivo human skin demonstrates the potential for superior LEKTI delivery compared to topical LEKTI application
- Preclinical data suggests ATR-12 can significantly reduce IL-36γ, a pro-inflammatory cytokine that drives Netherton syndrome

---

**Azitra, Inc.**

Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The Company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the Company’s library of strains for drug-like molecules. The Company’s initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which the Company considers to be an optimal therapeutic candidate species for engineering of dermatologic therapies. For more information, please visit [Azitra, Inc.](https://azitrainc.com).

**About Azitra, Inc.**

Azitra, Inc. is an early-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The Company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. This platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the Company’s library of strains for drug-like molecules. The Company’s initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which the Company considers to be an optimal therapeutic candidate species for engineering of dermatologic therapies. For more information, please visit [Azitra, Inc.](https://azitrainc.com).

**Preclinical data suggests ATR-12 can significantly reduce IL-36γ, a pro-inflammatory cytokine that drives Netherton syndrome**

- **Azitra’s candidate for Netherton syndrome**
- **Topical application of ATR-12 to ex vivo human skin demonstrates the potential for superior LEKTI delivery compared to topical LEKTI application**
- **Preclinical data suggests ATR-12 can significantly reduce IL-36γ, a pro-inflammatory cytokine that drives Netherton syndrome**